(Q40093043)

17 September 2017

1 reference

title

Selective alpha 1-adrenergic antagonists: therapeutically relevant antihypertensive agents (English)

1 reference

17 September 2017

Selective alpha1-adrenergic antagonists: Therapeutically relevant antihypertensive agents (English)

1 reference

https://api.crossref.org/works/10.1016/0002-9149(84)90829-4

Cardiology and cardiovascular medicine

13 August 2023

main subject

1 reference

https://api.crossref.org/works/10.1016/0002-9149(84)90829-4

13 August 2023

author name string

R. M. Graham

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6141721

13 August 2023

language of work or name

English

0 references

publication date

1 January 1984

1 reference

17 September 2017

27 January 1984

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=6141721

full work available at URL

13 August 2023

https://api.elsevier.com/content/article/PII:0002914984908294?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0002-9149(84)90829-4

https://api.elsevier.com/content/article/PII:0002914984908294?httpAccept=text/plain

13 August 2023

1 reference

https://api.crossref.org/works/10.1016/0002-9149(84)90829-4

American Journal of Cardiology

13 August 2023

published in

1 reference

17 September 2017

volume

53

1 reference

17 September 2017

issue

3

1 reference

17 September 2017

page(s)

16A-20A

1 reference

Chemical blockade of the sympathetic nervous system in essential hypertension; experience with oral therapy with 688-A (N-phenoxy isopropyl-N-benzyl-beta-chloroethylamine hydrochloride)

17 September 2017

cites work

2

1 reference

https://api.crossref.org/works/10.1016/0002-9149(84)90829-4

Dibenzyline: results of therapy in patients with hypertension and a comparison with hexamethonium, 1-hydrazinophthalazine and semipurified extracts of veratrum

13 August 2023

3

1 reference

https://api.crossref.org/works/10.1016/0002-9149(84)90829-4

Treatment of essential hypertension with B-alkylamines, especially dibenzyline

13 August 2023

4

1 reference

https://api.crossref.org/works/10.1016/0002-9149(84)90829-4

Alpha and beta adrenergic blockade in hypertension.

13 August 2023

5

1 reference

https://api.crossref.org/works/10.1016/0002-9149(84)90829-4

Adrenergic blocking agents

13 August 2023

6

1 reference

https://api.crossref.org/works/10.1016/0002-9149(84)90829-4

Haemodynamic effects of prazosin

13 August 2023

7

1 reference

https://api.crossref.org/works/10.1016/0002-9149(84)90829-4

Alpha blocking action of the antihypertensive agent, prazosin

13 August 2023

8

1 reference

https://api.crossref.org/works/10.1016/0002-9149(84)90829-4

Mechanism of the hypotensive action of prazosin

13 August 2023

9

1 reference

https://api.crossref.org/works/10.1016/0002-9149(84)90829-4

13 August 2023

Drug therapy. Prazosin

10

1 reference

https://api.crossref.org/works/10.1016/0002-9149(84)90829-4

Differentiation of Receptor Systems activated by Sympathomimetic Amines

13 August 2023

12

1 reference

https://api.crossref.org/works/10.1016/0002-9149(84)90829-4

A functional basis for classification of α-adrenergic receptors

13 August 2023

14

1 reference

https://api.crossref.org/works/10.1016/0002-9149(84)90829-4

.alpha.2 Adrenoceptors: classification, localization, mechanisms and targets for drugs

13 August 2023

15

1 reference

https://api.crossref.org/works/10.1016/0002-9149(84)90829-4

Preferential noradrenergic innervation of alpha-adrenergic receptors in vascular smooth muscle

13 August 2023

16

1 reference

https://api.crossref.org/works/10.1016/0002-9149(84)90829-4

Effect of desipramine on the effects of alpha-adrenoceptor inhibitors on pressor responses and release of norepinephrine into plasma of pithed rats

13 August 2023

17

1 reference

https://api.crossref.org/works/10.1016/0002-9149(84)90829-4

Pharmacological evidence for a functional role of the prejunctional alpha-adrenoreceptor in noradrenergic neurotransmission in the conscious rat.

13 August 2023

23

1 reference

https://api.crossref.org/works/10.1016/0002-9149(84)90829-4

Effects of alpha 1- and alpha 2-adrenoceptor blocking drugs on noradrenaline release rate in anesthetized rabbits

13 August 2023

25

1 reference

https://api.crossref.org/works/10.1016/0002-9149(84)90829-4

Hemodynamic and neuroendocrine responses to acute and chronic alpha-adrenergic blockade with prazosin and phenoxybenzamine.

13 August 2023

27

1 reference

https://api.crossref.org/works/10.1016/0002-9149(84)90829-4

Long-term hemodynamic and metabolic effects of trimazosin in essential hypertension.

13 August 2023

28

1 reference

https://api.crossref.org/works/10.1016/0002-9149(84)90829-4

Within patient comparison of prazosin and UK-33,274. A new alpha-adrenoceptor-antagonist

13 August 2023

30

1 reference

https://api.crossref.org/works/10.1016/0002-9149(84)90829-4

Antihypertensive effect of E-643, a new alpha-adrenergic blocking agent

13 August 2023

34

1 reference

https://api.crossref.org/works/10.1016/0002-9149(84)90829-4

Labetalol: A Review of Its Pharmacology, Pharmacokinetics, Clinical Uses and Adverse Effects

13 August 2023

36

1 reference

https://api.crossref.org/works/10.1016/0002-9149(84)90829-4

Relationship between the hypotensive and alpha-adrenoceptor blocking actions of prazosin

13 August 2023

37

1 reference

https://api.crossref.org/works/10.1016/0002-9149(84)90829-4

Antihypertensive and adrenoceptor blocking properties of new sulfonamide-substituted phenylethylamines

13 August 2023

38

1 reference

https://api.crossref.org/works/10.1016/0002-9149(84)90829-4

Influence of yohimbine on blood pressure, autonomic reflexes, and plasma catecholamines in humans

13 August 2023

39

1 reference

https://api.crossref.org/works/10.1016/0002-9149(84)90829-4

The effect of different classes of beta-antagonists on clinical and experimental hypertension

13 August 2023

42

1 reference

https://api.crossref.org/works/10.1016/0002-9149(84)90829-4

Physiologic evaluation of a new antihypertensive agent: prazosin HCl

13 August 2023

46

1 reference

https://api.crossref.org/works/10.1016/0002-9149(84)90829-4

Evaluation of beta blockade bendrofluazide, and prazosin in severe hypertension

13 August 2023

48

1 reference

https://api.crossref.org/works/10.1016/0002-9149(84)90829-4

Experience with prazosin in the treatment of patients with severe hypertension

13 August 2023

49

1 reference

https://api.crossref.org/works/10.1016/0002-9149(84)90829-4

Rapid control of serious high blood pressure with single large oral doses of prazosin

13 August 2023

50

1 reference

https://api.crossref.org/works/10.1016/0002-9149(84)90829-4

Prazosin: the first-dose phenomenon

13 August 2023

52

1 reference

https://api.crossref.org/works/10.1016/0002-9149(84)90829-4

Alpha-receptor function changes after the first dose of prazosin

13 August 2023

53

1 reference

https://api.crossref.org/works/10.1016/0002-9149(84)90829-4

Physiologic mechanisms opposing the hemodynamic effects of prazosin

13 August 2023

54

1 reference

https://api.crossref.org/works/10.1016/0002-9149(84)90829-4

Effectiveness of prazosin as initial antihypertensive therapy

13 August 2023

56

1 reference

https://api.crossref.org/works/10.1016/0002-9149(84)90829-4

Long-term use of prazosin in combination or alone for treating hypertension

13 August 2023

57

1 reference

https://api.crossref.org/works/10.1016/0002-9149(84)90829-4

Influence of dosage and dietary sodium on the first-dose effects of prazosin

13 August 2023

59

1 reference

https://api.crossref.org/works/10.1016/0002-9149(84)90829-4

Orthostatic hypotension after the first administration of prazosin in hypertensive patients: role of the plasma volume

13 August 2023

60

1 reference

https://api.crossref.org/works/10.1016/0002-9149(84)90829-4

Prazosin: severe side effects are dose-dependent

13 August 2023

61

1 reference

https://api.crossref.org/works/10.1016/0002-9149(84)90829-4

Prazosin first dose phenomenon during combined treatment with a beta-adrenoceptor blocker in hypertensive patients

13 August 2023

62

1 reference

https://api.crossref.org/works/10.1016/0002-9149(84)90829-4

Prazosin kinetics in essential hypertension

13 August 2023

63

1 reference

https://api.crossref.org/works/10.1016/0002-9149(84)90829-4

Prazosin kinetics in hypertension

13 August 2023

64

1 reference

https://api.crossref.org/works/10.1016/0002-9149(84)90829-4

Clinical pharmacokinetics of prazosin

13 August 2023

65

1 reference

https://api.crossref.org/works/10.1016/0002-9149(84)90829-4

Prazosin, pharmacokinetics and concentration effect

13 August 2023

66

1 reference

https://api.crossref.org/works/10.1016/0002-9149(84)90829-4

Prazosin protein binding in health and disease.

13 August 2023

67

1 reference

https://api.crossref.org/works/10.1016/0002-9149(84)90829-4

Dose-Dependent Bioavailability of Prazosin in Beagle Dogs

13 August 2023

68

1 reference

https://api.crossref.org/works/10.1016/0002-9149(84)90829-4

Indoramin and prazosin as adjuncts to beta adrenoceptor blockade in hypertension

13 August 2023

70

1 reference

https://api.crossref.org/works/10.1016/0002-9149(84)90829-4

13 August 2023

Identifiers

1 reference

17 September 2017

1 reference